SCHEMBL4308959

SCHEMBL4308959

Cc1ccsc1C(=O)Nc1cc(C(=O)NCCN2CCOCC2)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.56
▸ AURKB Q96GD4 1/20 0.56
▸ POLB P06746 1/20 0.45
▸ PARP1 P09874 1/20 0.45
▸ BCL3 P20749 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HPGDS O60760 1/20 0.43
▸ CYP2C19 P33261 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ FGFR1 P11362 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ FGFR3 P22607 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ WNT1 P04628 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308962 1.00 AURKA (0.56) AURKAAURKBPOLBPARP1BCL3
SCHEMBL4308985 0.88 AURKA (0.60) AURKAAURKBPARP1BCL3ALDH1A1
SCHEMBL4308994 0.88 AURKA (0.60) AURKAAURKBPARP1BCL3ALDH1A1
SCHEMBL14989354 0.88 AURKB (0.70) AURKAAURKBFGFR1MAPK1
SCHEMBL14989352 0.88 AURKB (0.70) AURKAAURKBFGFR1MAPK1
SCHEMBL4317390 0.87 AURKA (0.55) AURKAAURKBBCL3ALDH1A1GAA
SCHEMBL4317385 0.87 AURKA (0.55) AURKAAURKBBCL3ALDH1A1GAA
SCHEMBL4317605 0.87 AURKA (0.58) AURKAAURKBPOLBFGFR1FGFR2
SCHEMBL4317610 0.87 AURKA (0.58) AURKAAURKBPOLBFGFR1FGFR2
SCHEMBL4317282 0.87 AURKA (0.55) AURKAAURKBALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885POLB 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback